Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Increasing Age Of Mothers In Spain Leads To Rise In Mortality Rates
A new study examining the evolution of maternal mortality rates in Spain since 1996 shows a 17% increase in deaths. This trend is linked to the widespread increase in maternal age. The highest death rates are among foreign women and those who live in the province of Malaga.

Low Birth Weight May Mean Higher Risk For Kidney Disease
Parents of newborns who tip the scales at less than 5 ÷½ pounds should put some heavy thought to a possible future consequence: kidney disease. Low birth weight babies have a 70% greater risk of developing chronic kidney disease (CKD) in later life, according to research published in the August issue of the American Journal of Kidney Diseases, the official journal of the National Kidney Foundation.
News of the day
Secrets Revealed About How Disease-Causing DNA Mutations Occur
A team of Penn State scientists has shed light on the processes that lead to certain human DNA mutations that are implicated in hundreds of inherited diseases such as tuberous sclerosis and neurofibromatosis type 1. The results one day could influence the way couples who seek to have children receive genetic counseling. The team, led by Kateryna Makova, an associate professor of biology, also includes Erika Kvikstad, a graduate student in the Department of Biology, and Francesca Chiaromonte, an associate professor of statistics. Their findings will be published in the July 2009 issue of the journal Genome Research.
Public Health

Medivation Selects ProTrials To Conduct International Phase III Clinical Trials

ProTrials Research, Inc.TM, a leader in the clinical research organization industry, announced Medivation, Inc. (NASDAQ:MDVN) has chosen the company to conduct separate international Phase III clinical trials for two novel treatments. ProTrials will test MDV3100 for treating prostate cancer and the investigational drug Dimebon TM as a treatment for Huntington"s disease. Due to the complex nature of these Phase III trials, Medivation again selected ProTrials as its contract research organization partner because of ProTrials" successful past performance with the company"s Phase I, II and III trials. "We are working with ProTrials specifically because of its people and their long track records of conducting clinical trials," noted Lynn Seely, M.D., chief medical officer at Medivation. "While many CROs have research managers that are industry veterans, it"s unusual to find a CRO offering such deep experience levels across the team." ProTrials will oversee the Huntington"s trial across the United States, Canada and Europe, and the United States and Canada for the prostate cancer trial. Both clinical trials are expansive in nature, involving hundreds of patients and about 125 test sites total. They will both be randomized and placebo-controlled. "Medivation"s repeated selection of ProTrials as a clinical trials partner is a nod to our track record of efficiency, cost effectiveness and most importantly, our GCP compliance in conducting clinical trials," said ProTrials CEO Jodi Andrews. "With prostate cancer being one of the most prevalent types of cancer in men, and Huntington"s disease having no treatments currently approved by the U.S. Food and Drug Administration, these Phase III clinical trials are crucial for moving potentially life-saving treatments to market." Visitors to the upcoming 2009 American Society for Clinical Oncology (ASCO), being held May 29-June 2 at the Orange County Convention Center in Orlando, FL, can learn more about ProTrials in booth #703. ProTrials will also be attending the 45th Annual Meeting of the Drug Information Association (DIA), being held June 21-25 at the San Diego (CA) Convention Center, and will be in booth #1215. ProTrials Research, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009